Alexandra Song
About
Alexandra Song is a scholar working on Genetics, Surgery and Immunology.
According to data from OpenAlex, Alexandra Song has authored 31 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 11 papers in Surgery and 10 papers in Immunology. Recurrent topics in Alexandra Song's work include Inflammatory Bowel Disease (18 papers), Eosinophilic Esophagitis (11 papers) and Immunodeficiency and Autoimmune Disorders (8 papers). Alexandra Song is often cited by papers focused on Inflammatory Bowel Disease (18 papers), Eosinophilic Esophagitis (11 papers) and Immunodeficiency and Autoimmune Disorders (8 papers). Alexandra Song collaborates with scholars based in United States, Germany and Canada. Alexandra Song's co-authors include Martina Kron, Samir Tari, Andrew D. Dick, Glenn J. Jaffe, Anne Camez, Nisha V. Kwatra, Antoine P. Brézin, Carlos Pavésio, David K. Scales and Talin Barisani‐Asenbauer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.
In The Last Decade
Alexandra Song
27 papers receiving 903 citations
Hit Papers
Peers
Alexandra Song
Nisha V. Kwatra United States
P. Bielefeld France
Deshka Doycheva Germany
A Linssen Netherlands
Dara J. Kilmartin Ireland
Stephen C. Foster United States
Trudy M. Doyle United States
Susan Lightman United Kingdom
S. Biester Germany
Hanns-Martin Lorenz Germany
Citations per year, relative to Alexandra Song Alexandra Song (= 1×)
peers
Nisha V. Kwatra
Countries citing papers authored by Alexandra Song
Since
Specialization
Citations
This map shows the geographic impact of Alexandra Song's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra Song with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra Song more than expected).
Fields of papers citing papers by Alexandra Song
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alexandra Song. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra Song. The network helps show where Alexandra Song may publish in the future.
Co-authorship network of co-authors of Alexandra Song
This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra Song. A scholar is included among the top collaborators of Alexandra Song based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra Song. Alexandra Song is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Panaccione, Remo, Marc Ferrante, Iris Dotan, et al.. (2025). Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment. Clinical Gastroenterology and Hepatology. 23(11). 2012–2022.e6.
2.
Panaccione, Remo, Marla C. Dubinsky, Tadakazu Hisamatsu, et al.. (2025). DOP016 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension. Journal of Crohn s and Colitis. 19(Supplement_1). i113–i115.
3.
Ferrante, Marc, Remo Panaccione, Jean‐Frédéric Colombel, et al.. (2024). DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension. Journal of Crohn s and Colitis. 18(Supplement_1). i167–i169.
4.
Atreya, Raja, Marc Ferrante, Remo Panaccione, et al.. (2024). Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. Journal of Crohn s and Colitis. 19(4).
5.
Geng, Shan, et al.. (2024). RNAs associated with oxidative stress and apoptosis show anticancer effects of Flos Sophorae flavonoids extract on human hepatoma cells. International Journal of Biological Macromolecules. 282(Pt 1). 136750–136750.
6.
Cestari, Tânia Ferreira, Cacilda da Silva Souza, Luna Azulay‐Abulafia, et al.. (2024). Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. Anais Brasileiros de Dermatologia. 100(2). 260–271.
7.
Bobadilla, Ana Victoria Ponce, et al.. (2024). SERENE ER Analysis Part 1‐SERENE CD: Exposure‐Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease. Clinical Pharmacology in Drug Development. 13(9). 1024–1032.
8.
Ferrante, Marc, Peter M. Irving, María T. Abreu, et al.. (2023). Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial. Journal of Crohn s and Colitis. 18(3). 416–423.
9.
Loftus, Edward V., Jenny Griffith, Ezequiel Neimark, et al.. (2023). Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease. Advances in Therapy. 40(5). 2311–2325.
10.
Panaccione, Remo, David T. Rubin, Edward V. Loftus, et al.. (2023). Tu1730 LONG-TERM EFFICACY AND SAFETY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: 104-WEEK RESULTS FROM THE FORTIFY STUDY. Gastroenterology. 164(6). S–1098.
11.
Baert, Filip J., Raja Atreya, Yoichi Kakuta, et al.. (2022). DOP85 Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn’s Disease and inadequate response to risankizumab maintenance therapy. Journal of Crohn s and Colitis. 16(Supplement_1). i128–i128.
12.
Schreiber, Stefan, Marc Ferrante, Remo Panaccione, et al.. (2021). OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. Journal of Crohn s and Colitis. 15(Supplement_1). S026–S027.
13.
Bossuyt, Peter, Marc Ferrante, Filip Baert, et al.. (2021). OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. Journal of Crohn s and Colitis. 15(Supplement_1). S033–S034.
14.
Danese, Silvio, William J. Sandborn, Edward V. Loftus, et al.. (2020). S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study. The American Journal of Gastroenterology. 115(1). S325–S326.
15.
Rosenbaum, James T., Bahram Bodaghi, Cristóbal Couto, et al.. (2019). New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Seminars in Arthritis and Rheumatism. 49(3). 438–445.
16.
Jaffe, Glenn J., Andrew D. Dick, Antoine P. Brézin, et al.. (2016). Adalimumab in Patients with Active Noninfectious Uveitis. New England Journal of Medicine. 375(10). 932–943.
17.
Nguyen, Quan Dong, Pauline T. Merrill, Glenn J. Jaffe, et al.. (2016). Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet. 388(10050). 1183–1192.
18.
Suhler, Eric B., Glenn J. Jaffe, Quan Dong Nguyen, et al.. (2016). Long-Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study. Arthritis & Rheumatism. 68.
19.
Jaffe, Glenn J., Jennifer E. Thorne, David K. Scales, et al.. (2015). Adalimumab in Patients With Active, Non-infectious Uveitis Requiring High-dose Corticosteroids: the VISUAL-1 Trial. Investigative Ophthalmology & Visual Science. 56(7). 3115–3115.
20.
Jaffe, Glenn J., Jennifer E. Thorne, David K. Scales, et al.. (2015). SAT0523 Adalimumab in Patients with Active, Non-Infectious Uveitis Requiring High-Dose Corticosteroids: the Visual-1 Trial. Annals of the Rheumatic Diseases. 74. 849–850.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nisha V. Kwatra Breakdown of academic impact, for papers by P. Bielefeld Breakdown of academic impact, for papers by Deshka Doycheva Breakdown of academic impact, for papers by A Linssen Breakdown of academic impact, for papers by Dara J. Kilmartin Breakdown of academic impact, for papers by Stephen C. Foster Breakdown of academic impact, for papers by Trudy M. Doyle Breakdown of academic impact, for papers by Susan Lightman Breakdown of academic impact, for papers by S. Biester Breakdown of academic impact, for papers by Hanns-Martin Lorenz